Phase III trial of dalbavancin in patients with complicated skin and skin structure infections caused by gram-positive bacteria

Trial Profile

Phase III trial of dalbavancin in patients with complicated skin and skin structure infections caused by gram-positive bacteria

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2009

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Gram-positive infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 17 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top